Skip to main content
Clinical Trials/NCT03460158
NCT03460158
Completed
Phase 4

Prospective Evaluation of Minimally Invasive Facial Cosmetic Procedures Through Measured Volumetric Changes and Patient Reported Outcomes

University of Pennsylvania1 site in 1 country101 target enrollmentStarted: August 21, 2020Last updated:

Overview

Phase
Phase 4
Status
Completed
Enrollment
101
Locations
1
Primary Endpoint
Patient Satisfaction With Validated FACE-Q Aesthetics Survey

Overview

Brief Summary

A prospective, trial to quantitatively and qualitatively compare the dermal fillers for the treatment of age related aesthetic changes.

Detailed Description

Dermal fillers have been approved for the treatment of age related aesthetic changes, including facial volume loss, and attenuation of the static and dynamic rhytid. Despite widespread use of volumizing fillers there is little data quantifying the subjective benefit of these minimally invasive treatments from the patient perspective. Furthermore, there is little data comparing the subjective benefit with true objective volumetric results. Such data will provide much needed information for patient counselling and treatment optimization for patient perceived outcomes.

This study is to determine the patient reported outcomes of three different dermal fillers and establish the volumetric changes over 90 days. Screening will be performed during the patient's office visit. Approximately 100 patients will be enrolled. Patients will participate up to 90 days (Day 1, 14 days, 28 days, and 90 days).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
40 Years to 65 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Female patients 40 - 65 years of age

Exclusion Criteria

  • Male patients
  • Prior surgical facial rejuvenation procedures
  • Neck lift
  • Blepharoplasty
  • Facial fat grafting
  • Prior minimally invasive rejuvenation procedure ≤ 12 months
  • Known contraindications to devices or drugs used in this study
  • Facial paralysis
  • Congenital facial asymmetry
  • Pregnant women

Arms & Interventions

Restylane-L®, Restylane-L® Lyft, and Restylane Silk®

Experimental

Hyaluronic acid

Intervention: Restylane-L® (Drug)

Restylane-L®, Restylane-L® Lyft, and Restylane Silk®

Experimental

Hyaluronic acid

Intervention: Restylane-L® Lyft (Drug)

Restylane-L®, Restylane-L® Lyft, and Restylane Silk®

Experimental

Hyaluronic acid

Intervention: Restylane Silk® (Drug)

Outcomes

Primary Outcomes

Patient Satisfaction With Validated FACE-Q Aesthetics Survey

Time Frame: 2 week post injections

Absolute Change of the Patient Satisfaction using the validated FACE-Q Aesthetics questionnaire for patient reported assessment of treatment by domain. The absolute change from the patient reported outcome score prior to injection to the patient reported score immediate post-injection. Increase in numeric value indicates the larger patient reported improvement, except for psychosocial distress module where a decrease in numeric value indicates patient improvement. Maximum change 99 and Minimum Change 0.

Secondary Outcomes

  • Correlate Patient Satisfaction With Volumetric Measurements(upto 90 days)
  • Volumetric Changes of Treatment(immediately post injection, 2 weeks, 4 weeks, and 12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials